Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases

Journal of Thoracic Oncology

Volumn 12, Issue 1, 2017, Pages 152-156

  Klempner, Samuel J ^a,b   Borghei, Ali ^a   Hakimian, Behrooz ^b   Ali, Siraj M ^c   Ou, Sai Hong Ignatius ^d  

^a Angeles Clinic and Research Institute   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c FOUNDATION MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain metastases; Cabozantinib; Comprehensive genomic profiling; Crizotinib; MET exon 14; NSCLC

Indexed keywords

AMINOTRANSFERASE; CABOZANTINIB; LIVER ENZYME; SCATTER FACTOR RECEPTOR; ANILIDE; MET PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; TUMOR MARKER;

AGED; ARTICLE; BRAIN DISEASE; BRAIN FUNCTION; BRAIN METASTASIS; CANCER GROWTH; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CASE REPORT; DISEASE ASSOCIATION; EXON; GENE AMPLIFICATION; GENE FUNCTION; GENOMICS; HUMAN; HYBRID; INTRACRANIAL ACTIVITY; LIVER METASTASIS; LOBECTOMY; MALE; MEDICAL HISTORY; MET ONCOGENE; NON SMALL CELL LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTO ONCOGENE; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; BRAIN TUMOR; GENETICS; LUNG TUMOR; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY;

AGED; ANILIDES; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; EXONS; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES;

EID: 85015267434     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.09.127     Document Type: Article

References (16)

1. 1 Frampton, G.M., Ali, S.M., Rosenzweig, M., et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5 (2015), 850–859.
2. 2 Paik, P.K., Drilon, A., Fan, P.D., et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 5 (2015), 842–849.
3. 3 Costa, D.B., Shaw, A.T., Ou, S.H., et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33 (2015), 1881–1888.
4. 4 Gadgeel, S.M., Gandhi, L., Riely, G.J., et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15 (2014), 1119–1128.
5. 5 Frampton, G.M., Fichtenholtz, A., Otto, G.A., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
6. 6 Costa, D.B., Kobayashi, S., Pandya, S.S., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29 (2011), e443–e445.
7. 7 Klempner, S.J., Ou, S.H., Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS. Chin Clin Oncol, 4, 2015, 20.
8. 8 Schrock, A.B., Frampton, G.M., Suh, J., et al. Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations. J Thorac Oncol 11 (2016), 1493–1502.
9. 9 Liu, S.Y., Gou, L.Y., Li, A.N., et al. The unique characteristics of MET exon 14 mutation in Chinese patients with NSCLC. J Thorac Oncol 11 (2016), 1503–1510.
10. 10 Ou, S.-H.I., Young, L., Schrock, A.B., et al. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol 12 (2017), 137–140.
11. 11 Heist, R.S., Sequist, L.V., Borger, D., et al. Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping. J Thorac Oncol 11 (2016), 1242–1245.
12. 12 Hughes, P.E., Rex, K., Caenepeel, S., et al. In vitro and in vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models. Mol Cancer Ther 15 (2016), 1568–1579.
13. 13 Tiedt, R.E., Degenkolbe, E., Furet, P., et al. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 71 (2011), 5255–5264.
14. 14 Yan, S.B., Peek, V.L., Ajamie, R., et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest New Drugs 31 (2013), 833–844.
15. 15 Hart, C.D., De Boer, R.H., Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther 6 (2013), 1–7.
16. 16 Choueiri, T.K., Escudier, B., Powles, T., et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1814–1823.